These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27804297)

  • 1. Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase.
    Butler KV; Ma A; Yu W; Li F; Tempel W; Babault N; Pittella-Silva F; Shao J; Wang J; Luo M; Vedadi M; Brown PJ; Arrowsmith CH; Jin J
    J Med Chem; 2016 Nov; 59(21):9881-9889. PubMed ID: 27804297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.
    Milite C; Feoli A; Viviano M; Rescigno D; Mai A; Castellano S; Sbardella G
    ChemMedChem; 2016 Aug; 11(16):1680-5. PubMed ID: 27411844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
    Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J
    J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wasney GA; Dong A; Barsyte D; Kozieradzki I; Senisterra G; Chau I; Siarheyeva A; Kireev DB; Jadhav A; Herold JM; Frye SV; Arrowsmith CH; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2009 Dec; 52(24):7950-3. PubMed ID: 19891491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
    Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
    J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
    Eggert E; Hillig RC; Koehr S; Stöckigt D; Weiske J; Barak N; Mowat J; Brumby T; Christ CD; Ter Laak A; Lang T; Fernandez-Montalvan AE; Badock V; Weinmann H; Hartung IV; Barsyte-Lovejoy D; Szewczyk M; Kennedy S; Li F; Vedadi M; Brown PJ; Santhakumar V; Arrowsmith CH; Stellfeld T; Stresemann C
    J Med Chem; 2016 May; 59(10):4578-600. PubMed ID: 27075367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
    Cowen SD; Russell D; Dakin LA; Chen H; Larsen NA; Godin R; Throner S; Zheng X; Molina A; Wu J; Cheung T; Howard T; Garcia-Arenas R; Keen N; Pendleton CS; Pietenpol JA; Ferguson AD
    J Med Chem; 2016 Dec; 59(24):11079-11097. PubMed ID: 28002961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Characterizations of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Scaffold Hopping- and 2D-Molecular Fingerprint-Based Similarity Search.
    Ding H; Lu WC; Hu JC; Liu YC; Zhang CH; Lian FL; Zhang NX; Meng FW; Luo C; Chen KX
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain.
    Guo Y; Mao X; Xiong L; Xia A; You J; Lin G; Wu C; Huang L; Wang Y; Yang S
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):8760-8765. PubMed ID: 33511756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Nucleosome Substrates Improves Binding of SAM Analogs to SETD8.
    Strelow JM; Xiao M; Cavitt RN; Fite NC; Margolis BJ; Park KJ
    J Biomol Screen; 2016 Sep; 21(8):786-94. PubMed ID: 27369108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.
    Xiong Y; Li F; Babault N; Wu H; Dong A; Zeng H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
    Bioorg Med Chem; 2017 Aug; 25(16):4414-4423. PubMed ID: 28662962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
    Lenstra DC; Al Temimi AHK; Mecinović J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights for the design of protein lysine methyltransferase G9a inhibitors.
    Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
    Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using 'biased-privileged' scaffolds to identify lysine methyltransferase inhibitors.
    Kashyap S; Sandler J; Peters U; Martinez EJ; Kapoor TM
    Bioorg Med Chem; 2014 Apr; 22(7):2253-60. PubMed ID: 24650704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent inhibition of NSD1 histone methyltransferase.
    Huang H; Howard CA; Zari S; Cho HJ; Shukla S; Li H; Ndoj J; González-Alonso P; Nikolaidis C; Abbott J; Rogawski DS; Potopnyk MA; Kempinska K; Miao H; Purohit T; Henderson A; Mapp A; Sulis ML; Ferrando A; Grembecka J; Cierpicki T
    Nat Chem Biol; 2020 Dec; 16(12):1403-1410. PubMed ID: 32868895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
    Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of the first fragment hits for SETDB1 Tudor domain.
    Mader P; Mendoza-Sanchez R; Iqbal A; Dong A; Dobrovetsky E; Corless VB; Liew SK; Houliston SR; De Freitas RF; Smil D; Sena CCD; Kennedy S; Diaz DB; Wu H; Dombrovski L; Allali-Hassani A; Min J; Schapira M; Vedadi M; Brown PJ; Santhakumar V; Yudin AK; Arrowsmith CH
    Bioorg Med Chem; 2019 Sep; 27(17):3866-3878. PubMed ID: 31327677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2.
    Zheng W; Ibáñez G; Wu H; Blum G; Zeng H; Dong A; Li F; Hajian T; Allali-Hassani A; Amaya MF; Siarheyeva A; Yu W; Brown PJ; Schapira M; Vedadi M; Min J; Luo M
    J Am Chem Soc; 2012 Oct; 134(43):18004-14. PubMed ID: 23043551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.
    Vaswani RG; Gehling VS; Dakin LA; Cook AS; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Cantone N; Cummings RT; Normant E; Bellon SF; Albrecht BK; Harmange JC; Trojer P; Audia JE; Zhang Y; Justin N; Chen S; Wilson JR; Gamblin SJ
    J Med Chem; 2016 Nov; 59(21):9928-9941. PubMed ID: 27739677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibitors of SETD8 with cellular activity.
    Blum G; Ibáñez G; Rao X; Shum D; Radu C; Djaballah H; Rice JC; Luo M
    ACS Chem Biol; 2014 Nov; 9(11):2471-8. PubMed ID: 25137013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.